Literature DB >> 9020144

Compartmentalized activation of the high affinity immunoglobulin E receptor within membrane domains.

K A Field1, D Holowka, B Baird.   

Abstract

The earliest known step in the activation of the high affinity IgE receptor, FcepsilonRI, is the tyrosine phosphorylation of its beta and gamma subunits by the Src family tyrosine kinase, Lyn. We report here that aggregation-dependent association of FcepsilonRI with specialized regions of the plasma membrane precedes its tyrosine phosphorylation and appears necessary for this event. Tyrosine phosphorylation of beta and gamma occurs in intact cells only for FcepsilonRI that associate with these detergent-resistant membrane domains, which are enriched in active Lyn. Furthermore, efficient in vitro tyrosine phosphorylation of FcepsilonRI subunits occurs only for those associated with isolated domains. This association and in vitro phosphorylation are highly sensitive to low concentrations of detergent, suggesting that lipid-mediated interactions with Lyn are important in FcepsilonRI activation. Participation of membrane domains accounts for previously unexplained aspects of FcepsilonRI-mediated signaling and may be relevant to signaling by other multichain immune receptors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9020144     DOI: 10.1074/jbc.272.7.4276

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  102 in total

1.  Pulse EPR detection of lipid exchange between protein-rich raft and bulk domains in the membrane: methodology development and its application to studies of influenza viral membrane.

Authors:  K Kawasaki; J J Yin; W K Subczynski; J S Hyde; A Kusumi
Journal:  Biophys J       Date:  2001-02       Impact factor: 4.033

2.  Sequential requirements of the N-terminal palmitoylation site and SH2 domain of Src family kinases in the initiation and progression of FcepsilonRI signaling.

Authors:  Z i Honda; T Suzuki; H Kono; M Okada; T Yamamoto; C Ra; Y Morita; K Yamamoto
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

3.  Mutant RBL mast cells defective in Fc epsilon RI signaling and lipid raft biosynthesis are reconstituted by activated Rho-family GTPases.

Authors:  K A Field; J R Apgar; E Hong-Geller; R P Siraganian; B Baird; D Holowka
Journal:  Mol Biol Cell       Date:  2000-10       Impact factor: 4.138

4.  Structure-function analysis of Lyn kinase association with lipid rafts and initiation of early signaling events after Fcepsilon receptor I aggregation.

Authors:  M Kovárová; P Tolar; R Arudchandran; L Dráberová; J Rivera; P Dráber
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

5.  Plasma membrane rafts play a critical role in HIV-1 assembly and release.

Authors:  A Ono; E O Freed
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

Review 6.  Mast cells. Receptors, secretagogues, and signaling.

Authors:  Bhavya B Sharma; John R Apgar; Fu-Tong Liu
Journal:  Clin Rev Allergy Immunol       Date:  2002-04       Impact factor: 8.667

7.  Cytoskeleton-dependent membrane domain segregation during neutrophil polarization.

Authors:  S Seveau; R J Eddy; F R Maxfield; L M Pierini
Journal:  Mol Biol Cell       Date:  2001-11       Impact factor: 4.138

8.  A 2D-ELDOR study of the liquid ordered phase in multilamellar vesicle membranes.

Authors:  Antonio J Costa-Filho; Yuhei Shimoyama; Jack H Freed
Journal:  Biophys J       Date:  2003-04       Impact factor: 4.033

Review 9.  Lipid rafts, fluid/fluid phase separation, and their relevance to plasma membrane structure and function.

Authors:  Prabuddha Sengupta; Barbara Baird; David Holowka
Journal:  Semin Cell Dev Biol       Date:  2007-07-24       Impact factor: 7.727

10.  CD33 recruitment inhibits IgE-mediated anaphylaxis and desensitizes mast cells to allergen.

Authors:  Shiteng Duan; Cynthia J Koziol-White; William F Jester; Scott A Smith; Corwin M Nycholat; Matthew S Macauley; Reynold A Panettieri; James C Paulson
Journal:  J Clin Invest       Date:  2019-02-18       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.